ERNI Is On HIGH ALERT! Dear Fellow Trader, On The Heels of hugely successful picks, we could not be more excited to bring our members our next ALERT! Our New Breakout Play Is:
Website: www.rewardsnexus.com ERNI Is On Immediate ALERT! About Rewards Nexus Inc.
Rewards Nexus offers U.S. retailers innovative loyalty solutions including rewards and gift card programs, along with emerging marketing strategies aimed at consumers. Rewards Nexus grows through acquisitions and cooperative agreements with companies that have high potential and capabilities of achieving sustainable growth, resulting in a rapidly acquiring market share. The Company builds key strategies for its subsidiaries while providing financing and operational business support.
ERNI through its subsidiaries operates in the loyalty-rewards industry in the United States. ERNI offers the Earn IQ rewards program, a marketing solution for small to medium sized businesses that allows consumers to purchase items either online or physically from participating retailers in the Earn IQ network and earn points based on their total bill, primarily focusing on the dining and entertainment sector.
Could ERNI Be The Next Groupon Operating in the $40 billion loyalty rewards space, the company has managed to carve out a place for itself in a very competitive space indeed. Groupon alone is worth more than $6 billion based on current pricing, and multi-billion dollar acquisitions are now becoming vogue in the ever-expanding industry.
ERNI also provides consumers with opportunities to interact and engage with online and mobile products; and develops gift card processing solutions. It primarily focuses on various business sectors, including the customer loyalty management market, the gift card industry, the online food ordering industry, and the marketing consulting industry.
Americans accumulate approximately $48 billion in rewards points and miles annually, according to the results of a first-ever study on the perceived dollar value of loyalty programs that illustrates the real economic power of these programs for consumers, issuers, merchants and manufacturers.
Out of roughly $48 billion worth of perceived value in reward points and miles American businesses issue annually, at least one-third, representing $16 billion in value, goes unredeemed by consumers, according to the study, titled 2011 Forecast of U.S. Consumer Loyalty Program Points Value.
This is excellent news for a company like ERNI who is seeking to tap into the heart of consumer loyalty.
ERNI has taken some HUGE steps forward recently, placing the Company in an excellent position for growth. They have released quite a few significant press releases all of which indicate the Company`s Huge Growth potential ERNI just announced Production Order for 100,000 New Earn IQ Cards.
ERNI recently announced the launch of the Earn IQ Independent Sales Reps Program which suggests on putting up to 100 representatives in place in the Tri-State area (New York, New Jersey and Connecticut) during the next 6 months.
Keep in mind that one of ERNI`s competitor (GrubHub) is just coming off its IPO – which is huge news for bullish traders and more proof positive that the loyalty rewards space sector is hot! If traders are in doubt about ERNI`s growth potential then the big news announced today would certainly have put paid to that.
If traders are impressed with ERNI`s growth potential so far wait until you look at ERNI`s recent Bomb Shell of news below! ERNI recently announced that they have entered into a non-binding letter of intent (LOI) with Hotdeal Asia Limited (HotDeal) which outlines the general terms and conditions pursuant to which Rewards Nexus and HotDeal will negotiate the forming of a Joint Venture for combining business operations. (Click Here for Full Press Release) HotDeal is a Hong Kong based company which was created to provide restaurants with an innovative platform, which will communicate and publish real-time and instant offers to nearby consumers.
This is just one more big reason why ERNI is to be taken seriously! ERNI is showing that we have 5 BUYS and 1 HOLD all indicating uptrends according to Barchart.com! Go here to verify (5 Buys & 1 Hold) Composite Indicators Below:
TrendSpotter: Buy 7 Day Average Directional Indicator: Buy 10 – 8 Day Moving Average Hilo Channel: Buy 20 Day Moving Average vs Price: Buy 20 – 50 Day MACD Oscillator: Buy 20 Day Bollinger Bands: Hold Short Term Indicators Average: 80% Let`s KICK The Week Off With A BIG WINNER!! I recommend starting your own research on ERNI immediately! This could be a Huge Stock Play. So move quickly to enjoy the rewards! Now let`s grab some BIG GAINS… KABOOM!!!! Start Your Research Now! As always we encourage subscribers to do their own due diligence and visit the company website: www.rewardsnexus.com Happy Trading!! Your OTCtipReporter Team DONT MISS ANOTHER HOT OPPORTUNITY TO MAKE HUGE PROFITS! Help Spread the word about OTCtipReporter! You can call us toll free at: 1-800-850-9305 Offices are open Monday through Friday, 9:30 am to 4:00 pm EST Email: office@OTCtipReporter.com www.OTCtipReporter.com Investor Awareness and IR Services If you are interested in our Investor Awareness and IR Services contact us at 1-800-850-9305 or email us at office@OTCtipReporter.com GENERAL NOTICE AND DISCLAIMER – PLEASE READ CAREFULLY The companies that are discussed on OTCtipReporter.com have not approved the statements made. This opinion contains forward-looking statements that involve risks and uncertainties. A company`s actual results could differ materially from those described in any forward-looking statements or announcements discussed herein. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. OTCtipReporter.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Nor are any of its officers, affiliates, or employees. Please consult a broker before purchasing or selling any securities viewed on OTCtipReporter.com or mentioned herein.
Affiliates, officers, directors and employees of OTCtipReporter.com may have also bought or may buy shares of companies mentioned herein and may profit in the event those shares rise in value.
OTCtipReporter.com wi ll not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make their own decision based on his or her judgment of the market. This advertisement is not a solicitation or recommendation to buy, sell or hold securities and does not provide an analysis of the financial position of the company. We recommend you use the information found in this advertisement as an initial starting point for conducting your own research on the advertised company in order to determine your own personal opinion of the company before investing. All statements and opinions contained in this advertisement are the sole opinion of the authors and are subject to change without notice. We are not liable for any investment decisions by our readers. Readers should independently investigate and fully understand all risks before investing. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser or broker prior to completing any such purchase or sale decision. We are not registered investment advisers, or broker-dealers, or members of any financial regulatory bodies. Furthermore, our associates and/or employees and/or principals may have stock positions in advertised companies purchased in the open market or in private transactions.
These positions may be liquidated, without prior notification, even after we have made positive comments regarding the advertised company. The receipt of this information constitutes your acceptance of these terms and conditions. Reading this advertisement shall not create under any circumstances an offer to buy or sell stock in any company advertised. Nor shall it create any principal-agent relationship between the reader and us. Void where prohibited. Information within this advertisement contains “forward looking” statements within the meaning of Section-27(a) of the U.S. Securities Act-of-1933 and Section 21(e) of t he U.S.
Securities Exchange Act-of -934. Neither OTCtipReporter.com, its officers, affiliates, or employees is a broker-dealer. The information on OTCtipReporter.com, including the opinions expressed and the statements made within, is for informational and advertising purposes only and should not be construed as investment-advice, and does not constitute an offer to sell any securities, nor is it to be construed as a solicitation to purchase any securities in any state or other jurisdiction where the offer or sale is not permitted. The information to prepare this report is believed to be from reliable sources, but no representation is made as to the accuracy or completeness of such information. Investment in securities carries a high degree of risk and involves risks and uncertainties, which may result in investors losing all of their invested capital. Past performance does not guarantee future results. The information contained herein contains “forward-looking statemen ts,” within the meaning of Section-27A of the Securities Act-of-1933 and Section 21E of the Securities Exchange Act-of-1934.
Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or performance may be forward-looking statements. Factors that could cause actual results to differ materially include but are not limited to adverse economic conditions, intense competition, lack of meaningful research results, inadequate capital, termination of contracts or agreements, adv erse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other key personnel, and other risks detailed in the reports filed with the Securities and Exchange Commission by the companies who are mentioned in this periodical. Readers should consult with their own professional investment, tax and portfolio advisors before making any investment decision and should independently verify all information herein.
More complete information about any of the companies mentioned in this periodical is available from the website of the Securities and Exchange Commission, at sec.gov, and copies of their filings may be read without charge and copies obtained at prescribed rates from the public reference facilities of the Commission, at 450 Fifth Street, NW, Washington, DC 20549.
Buying and Selling of Shares OTCtipReporter.com intends to sell its shares. OTCtipReporter.com may sell its shares for less than target prices given in opinions.
OTCtipReporter.com affiliates, officers, directors and employees may have also bought or may buy the shares discussed in this report and may profit in the event those shares rise in value.
OTCtipReporter.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. There are risks involved Always remember that OTCtipReporter.com are not analysts and investing in securities such as the ones listed within are for high risk tolerant individuals only and not the general public. Whether you are an experienced investor or not you should always consult with a broker before purchasing or selling any securities viewed on OTCtipReporter.com. If at any time you wish to be removed from our list simply